Travere Therapeutics Q3 2025 Earnings Report

Travere Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.31
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Travere Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Travere Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 10/30/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, October 30, 2025
• Conference Call Time: 8:30AM ET

Travere Therapeutics (NASDAQ:TVTX) (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S. Food and Drug Administration for the treatment of adult and pediatric patients with focal segmental glomerulosclerosis (FSGS). Travere is also pursuing regulatory submissions for sparsentan in immunoglobulin A nephropathy (IgAN), with ongoing clinical trials exploring its long-term safety and efficacy. In addition to its renal pipeline, Travere has expanded its portfolio through a collaboration with Reata Therapeutics to develop anion transport modulators for pediatric cystic fibrosis.

Originally known as Retrophin, the company rebranded as Travere Therapeutics in December 2020 to better reflect its specialized focus on rare kidney diseases. Since the rebranding, Travere has advanced multiple late‐stage clinical programs and established a commercial infrastructure to support the launch and distribution of its therapies. The company maintains partnerships with academic research centers, patient advocacy organizations and global regulatory bodies to accelerate development timelines.

Headquartered in San Diego, Travere serves patients primarily in the United States while conducting clinical trials and seeking regulatory approvals in Europe and other international markets. The company’s leadership team is led by President and Chief Executive Officer Stacy Ennis, who brings extensive experience in biotechnology and rare disease drug development. Under her direction, Travere continues to build its pipeline and support communities impacted by rare and serious conditions.